Investor information
Vicapsys Life Sciences, Inc. is quoted on OTC Markets under the symbol VICP. The company provides its disclosure through the OTC Markets Disclosure & News Service.
- Issuer
- Vicapsys Life Sciences, Inc.
- Disclosure
- OTC Markets Disclosure & News Service
- Operating subsidiary
- Stateline Distributors of Puerto Rico, Inc.
- Headquarters
- Miami, Florida
Why Vicapsys
- A licensed, operating base. Stateline Distributors of Puerto Rico: wholesale drug distributor and specialty biologics licenses, 400+ active healthcare accounts, and 15,000+ SKUs across all 50 states on the Drugzone title model.
- A contracting advantage. A teaming agreement with a tribally owned, SBA-certified 8(a) partner for sole-source and set-aside federal awards at IHS, VA and DoD; VA and DoD alone spend more than $21 billion a year on pharmaceuticals.3 4
- An owned product with no new clinical risk. NitroMist®, an FDA-approved nitroglycerin lingual aerosol with peak sales of about US$40 million a year under prior ownership; definitive purchase agreement signed.
- Retained upside. VICAPSYN™, an immune-isolation platform for cell replacement in type 1 diabetes, licensed from Massachusetts General Hospital: in a 2023 primate pilot, encapsulated islets survived six months without systemic immunosuppression or foreign-body response. Research stage, held at the parent.
Figures as of October 2026. Peak sales and SKU access per management. Sources are listed on the platform page.
Press releases and disclosure
| Date | Title | Type | Read |
|---|---|---|---|
| October 5, 2026 | Housekeeping starts with branding: Vicapsys adopts a new corporate identity by FutureBrand | Press release | On this site ACCESS Newswire |
| September 25, 2026 | Vicapsys announces Advisory Board following completion of Stateline merger | Press release | On this site ACCESS Newswire |
| September 23, 2026 | OTC Markets disclosure application filed | Disclosure | OTC Markets |
| September 22, 2026 | Vicapsys completes reverse merger with Stateline Distributors of Puerto Rico and signs definitive agreement to acquire NitroMist® | Press release | On this site ACCESS Newswire |
Older filings and disclosure statements: OTC Markets disclosure for VICP.
Investor updates
Corporate governance
- Board of Directors
- Armando Rubio (Chairman); Jean Dominguez
- Executive officers
- Armando Rubio, Chief Executive Officer; Jean Dominguez, President; Alberto Dominguez, Chief Financial Officer
- Advisory Board
- Eight members, announced September 25, 2026; advisors, not directors. Members
- Operating subsidiary
- Stateline Distributors of Puerto Rico, Inc., wholly owned since September 3, 2026
- Securities counsel
- Sichenzia Ross Ference Carmel LLP, New York
- Puerto Rico counsel
- Lcdo. Yussef Lamboy
Investor contact
Investor and media inquiries
Mailing address
Vicapsys Life Sciences, Inc.
c/o Stateline Distributors of Puerto Rico, Inc.
Mario Juliá Industrial Park
696 Calle B, Suite 4
San Juan, PR 00920
Forward-looking statements
This website contains forward-looking statements within the meaning of the federal securities laws, including statements about the expected benefits of the Stateline merger, the acquisition and relaunch of NitroMist®, federal and tribal contracting prospects, the VICAPSYN™ program and financing. These statements are based on current expectations and are subject to risks and uncertainties, including the possibility that pending transactions do not close on the terms described or at all, FDA delays, the absence of any assurance of contract awards, and the availability of financing. Actual results may differ materially. Forward-looking statements speak only as of the date they are made, and the company undertakes no obligation to update them except as required by law.
Nothing on this website constitutes an offer to sell or a solicitation of an offer to buy any securities of Vicapsys Life Sciences, Inc. Any offering of securities will be made only to eligible investors by means of the applicable offering documents.